Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-23

Clinical Trial Update: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema [Phase 3]

View source ↗

Summary

A Phase 3 trial is planned to compare AVT29 with Eylea HD in diabetic macular edema and is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AVT29 (aflibercept)
  • EYLEA HD (aflibercept)

Snippet

Sponsor: Alvotech Swiss AG | Conditions: Diabetic Macular Edema | Phase 3 | Status: NOT_YET_RECRUITING